Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

Safety Information

A-095

Supelco

Atomoxetine hydrochloride solution

1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C17H22ClNO
CAS Number:
82248-59-7
Molecular Weight:
291.82
EC Number:
200-659-6
MDL number:
MFCD06410992
UNSPSC Code:
41116107
PubChem Substance ID:
329770640
NACRES:
NA.24

grade

certified reference material

Quality Level

300

form

liquid

feature

SNAP-N-SPIKE®, SNAP-N-SHOOT®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

concentration

1.0 mg/mL in methanol (as free base)

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

forensics and toxicology

format

single component solution

storage temp.

−20°C

SMILES string

Cl.CNCC[C@@H](Oc1ccccc1C)c2ccccc2

InChI

1S/C17H21NO.ClH/c1-14-8-6-7-11-16(14)19-17(12-13-18-2)15-9-4-3-5-10-15;/h3-11,17-18H,12-13H2,1-2H3;1H/t17-;/m1./s1

InChI key

LUCXVPAZUDVVBT-UNTBIKODSA-N

Gene Information

human ... SLC6A2(6530)

Related Categories

General description

Atomoxetine is an attention-deficit hyperactivity disorder (ADHD) drug marketed in the US under the trade name Strattera®. This Certified Spiking Solution® is suitable for use in numerous testing applications such as clinical toxicology, forensic analysis, pharmaceutical research, urine drug testing, or calibrator preparation.

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Strattera is a registered trademark of Eli Lilly and Co.

Signal Word

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Target Organs

Eyes

Storage Class Code

3 - Flammable liquids

WGK

WGK 1

Flash Point(F)

49.5 °F - closed cup

Flash Point(C)

9.7 °C - closed cup

Regulatory Listings

Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.

FSL

Group 4: Flammable liquids
Alcohols
Hazardous rank II

ISHL Indicated Name

Substances Subject to be Indicated Names

ISHL Notified Names

Substances Subject to be Notified Names

JAN Code

A-095-CHK:
A-095-CC:
A-095-1ML:4548173320533

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Michael Turner et al.
Behavioural brain research, 243, 28-37 (2012-12-26)
Atomoxetine (ATX) is a commonly used non-stimulant treatment for Attention deficit hyperactivity disorder (ADHD). It primarily acts to increase noradrenalin levels; however, at higher doses it can increase dopamine levels. To date there has been no investigations into the effects
Dongyi Tony Du et al.
Medical care, 50(11), 987-992 (2012-10-11)
The Food and Drug Administration (FDA) issued a Public Health Advisory entitled "Suicidal Thinking in Children and Adolescents Being Treated with Strattera (Atomoxetine)" on September 29, 2005. At FDA's request, the manufacturer subsequently added a boxed warning to the drug's
Emilia Marchei et al.
Drug testing and analysis, 5(3), 191-195 (2012-09-20)
Atomoxetine (ATX) is a selective norepinephrine reuptake inhibitor approved since 2002 for the treatment of attention deficit hyperactivity disorder (ADHD) in children, adolescents, and adults as an alternative treatment to methylphenidate. Within the framework of a project evaluating the use
Hedi Schelleman et al.
PloS one, 8(1), e52991-e52991 (2013-02-06)
To compare the incidence rates of serious cardiovascular events in adult initiators of amphetamines or atomoxetine to rates in non-users. This was a retrospective cohort study of new amphetamines (n=38,586) or atomoxetine (n=20,995) users. Each medication user was matched to
Potential serious adverse interactions between linezolid and atomoxetine.
Arpit Aggarwal et al.
Journal of child and adolescent psychopharmacology, 22(5), 405-405 (2012-10-23)
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service